References
The uses of botulinum toxin A in facial aesthetics
Abstract
The demand for non-surgical facial rejuvenation procedures is rising, and they are more popular than ever, with the aesthetic uses of botulinum toxin dramatically changing the landscape of facial rejuvenation. Botulinum toxin is a neurotoxin that works within cholinergic synapses present at neuromuscular endplates, preventing the transmission of neurotransmitters, such as acetylcholine, from nerves to muscles. This interference with nerve impulses leads to the muscles being temporarily weakened (paralysis). Botulinum toxin A was approved by the US Food and Drug Administration (FDA) for use in the glabella in 2002, followed by crow's feet in 2013 and then the forehead in 2017, with other aesthetic uses being classed as off-license. Botulinum toxin A yields good results in carefully selected patients, and a thorough consultation should always take place. Consultations should include management of expectations and the explanation that botulinum toxin A works on dynamic lines, rather than static lines. Treatment areas can be split into the upper face (glabellar, transverse forehead lines and lateral orbicularis oculi); mid face (bunny lines and perioral vertical lip lines); and lower face (masseter hypertrophy, mentalis, platysmal bands and gummy smile). Each patient should be assessed individually to determine individual anatomy, including the size, strength and location of muscles, with doses being adjusted accordingly.
With the increase in minimally invasive cosmetic surgical techniques and the rising popularity of non-surgical interventions such as dermal fillers and botulinum toxins, it is no surprise that the demand for facial rejuvenation procedures are more popular than ever. The aesthetic uses of botulinum toxin may have been discovered incidentally, but they have dramatically changed the landscape of facial rejuvenation.
The purpose of this article is to explore botulinum toxin as a medication, as well as the various indications, techniques and complications associated with its uses in facial aesthetics.
Botulinum toxin is the exotoxin of Clostridium botulinum, which is a spore-forming, gram-positive anaerobic bacterium (Kedlaya, 2010). In total, seven different serotypes are produced by Clostridium botulinum, namely A, B, C (C1, C2), D, E, F and G. Although structurally similar, each serotype varies in size and cellular mechanism, and also in its clinical usefulness. All serotypes bind to the same receptors, but target different proteins within the synapse. Additionally, each serotype differs in its potency and duration of effect.
Register now to continue reading
Thank you for visiting Journal of Aesthetic Nurses and reading some of our peer-reviewed resources for aesthetic nurses. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Limited access to clinical or professional articles
-
New content and clinical newsletter updates each month